News & Perspective
Drugs & Diseases
CME & Education
Video
Decision Point

Specialty: Cardiology
Allergy & Immunology
Anesthesiology
Cardiology
Critical Care
Dermatology
Diabetes & Endocrinology
Emergency Medicine
Family Medicine
Gastroenterology
General Surgery
Hematology - Oncology
HIV/AIDS
Hospital Medicine
Infectious Diseases
Internal Medicine
Multispecialty
Nephrology
Neurology
Ob/Gyn & Women's Health
Oncology
Ophthalmology
Orthopedics
Pathology & Lab Medicine
Pediatrics
Plastic Surgery
Psychiatry
Public Health
Pulmonary Medicine
Radiology
Rheumatology
Transplantation
Urology
Today on Medscape
Business of Medicine
Medical Lifestyle
Science & Technology
Medical Students
Nurses
Pharmacists
Residents
Edition: English

Medscape

English
Deutsch
Español
Français
Português
UKNew

Univadis

Sign Up It's Free!
English Edition

Medscape

Univadis

    X
    Univadis from Medscape

    No Results

      Allergy & Immunology Anesthesiology Cardiology Critical Care Dermatology Diabetes & Endocrinology Emergency Medicine Family Medicine Gastroenterology General Surgery Hematology - Oncology HIV/AIDS Hospital Medicine Infectious Diseases Internal Medicine Multispecialty Nephrology Neurology Ob/Gyn & Women's Health Oncology Ophthalmology Orthopedics Pathology & Lab Medicine Pediatrics Plastic Surgery Psychiatry Public Health Pulmonary Medicine Radiology Rheumatology Transplantation Urology Today on Medscape Business of Medicine Medical Lifestyle Science & Technology Medical Students Nurses Pharmacists Residents
      News & Perspective Drugs & Diseases CME & Education Video Decision Point

      Cardiology

      Medscape News & Perspective

      Your one-stop resource for medical news, clinical reference, and education.

      UK News & Perspectives View All

        View All
         

        Featured Cardiology News & Perspectives

        • Semaglutide CV Benefits Irrespective of Weight Lost?
          ECO 2024
          Semaglutide CV Benefits Irrespective of Weight Lost?
          Medscape Medical News May 14, 2024  
          Semaglutide remains effective for weight loss at 4 years in people with preexisting cardiovascular disease and overweight/obesity but without T2D and provides CV benefits regardless of weight.
         

        Latest News View All

        View All
         

        Perspectives View All

        •  
          Coronary Artery Disease: The New Big C
          Commentary May 15, 2024    
          Bob Harrington interviews fellow cardiologist Mike McConnell about his new book Fight Heart Disease Like Cancer and the need to model heart disease prevention and treatment after cancer.
        View All

        Columnists

        mtv

         

        Journal Articles View All

        View All

        Medscape Essentials

         

        Cases & Quizzes View All

        View All
         

        Conferences View All

        • ACC 2024
          April 06-8, 2024 Atlanta, Georgia  
        • ISC 2024
          February 07-9, 2024 Phoenix, Arizona  
        • AHA 2023
          November 11-13, 2023 Philadelphia, Pennsylvania  
        View All
         

        Business of Medicine View All

        View All

        Medscape Editorial Collaborations

        Advisory Board

        EXECUTIVE EDITOR

        Chief Cardiology Correspondent
        Medscape Staff

        native callouts

        Find Us On
        About
        About Medscape Privacy Policy Editorial Policy Cookies Manage Preferences Terms of Use Advertising Policy Help Center
        Membership
        Become a Member About You Professional Information Newsletters & Alerts Market Research
        App
        Medscape
        WebMD Network
        Medscape Live Events WebMD MedicineNet eMedicineHealth RxList WebMD Corporate Medscape UK
        Editions
        English Deutsch Español Français Português UK
        All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC. This website also contains material copyrighted by 3rd parties.